Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria-Reference-Cited by-同舟云学术

Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria

Published:2004-02-05 Issue:6 Volume:350 Page:552-559
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hillmen Peter,Hall Claire,Marsh Judith C.W.,Elebute Modupe,Bombara Michael P.,Petro Beth E.,Cullen Matthew J.,Richards Stephen J.,Rollins Scott A.,Mojcik Christopher F.,Rother Russell P.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa031688

Cited by 521 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-infectivity efficacy and pharmacokinetics of WHO recommended single low-dose primaquine in children with acute Plasmodium falciparum in Burkina Faso: study protocol;Trials;2024-09-03

2. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

3. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05

4. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors;PLOS ONE;2024-07-29

5. Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics;Clinical Pharmacology & Therapeutics;2024-07-22